France's Sanofi has agreed to buy US-based Blueprint Medicines Corp. for over $9 billion to boost its position in rare ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and the EU, and a promising advanced and early-stage immunology pipeline. Furthermore, ...

Sanofi is acquiring Vigil Neuroscience, a biotech firm focused on novel neurodegenerative disease therapies, to boost its ...

Sanofi is joining its fellow drugmakers in trying to put new restrictions on savings sent to hospitals in a federal drug discount program. A spokesperson for Sanofi confirmed plans to implement a ...

The proposal from PAI Partners, challenging a US bidder, is the latest twist in a battle to win a 50% stake in Opella, the maker of France's best-selling drug. A consortium including French ...

LONDON, Jan 10 (Reuters) - Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.

Instead, French pharma Sanofi tops the ranking for 2023, coming after it revamped its corporate image, logo and digital communications last year. Novartis, always a major digital player ...

Pfizer in fact started the Big Pharma logo switch trend in early 2021, revealing the culling of its old logo, which was a very simple pill image ... In 2022, both Sanofi and GSK took a similar ...

Sanofi logo at the company's headquarters during the annual results news conference in Paris, France, February 4, 2022. Reuters Sanofi said on Thursday it won European Union approval for its COVID ...

Ces démarches qui visent aussi à réhabiliter l’image des laboratoires ne sont pas sans contreparties. "Poursuivre les miracles de la science pour améliorer la vie des gens", devient la nouvelle raison ...

Sanofi logo at the company's headquarters during the annual results news conference in Paris, France, February 4, 2022. Reuters / BENOIT TESSIER Sanofi plans to list its drug ingredients ...